Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
33%
Ph phase_2
3
50%
Ph phase_3
1
17%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
3(50.0%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(1)
Other(1)

Detailed Status

Recruiting3
Completed1
Active, not recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 23 (50.0%)
Phase 31 (16.7%)

Trials by Status

completed117%
active_not_recruiting117%
recruiting350%
unknown117%

Recent Activity

4 active trials
Showing 5 of 6
recruitingphase_2

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

NCT06517511
active_not_recruitingphase_2

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

NCT03995147
recruitingphase_2

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

NCT06647940
recruitingphase_1

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

NCT05577364
unknownphase_1

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

NCT04058470
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06517511Phase 2

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

Recruiting
NCT03995147Phase 2

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Active Not Recruiting
NCT06647940Phase 2

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial）

Recruiting
NCT05577364Phase 1

Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients

Recruiting
NCT04058470Phase 1

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Unknown
NCT00554164Phase 3

Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6